Skip directly to page options Skip directly to A-Z link
Volume 23, Number 3—March 2017
Research

Pulmonary Nontuberculous Mycobacteria–Associated Deaths, Ontario, Canada, 2001–2013

Theodore K. MarrasComments to Author , Michael A. Campitelli, Hong Lu, Hannah Chung, Sarah K. Brode, Alex Marchand-Austin, Kevin L. Winthrop, Andrea S. Gershon, Jeffrey C. Kwong1, and Frances B. Jamieson1
Author affiliations: Mount Sinai Hospital, Toronto, Ontario, Canada (T.K. Marras, S.K. Brode); University of Toronto, Toronto (T.K. Marras, S.K. Brode, A.S. Gershon, J.C. Kwong, F.B. Jamieson); University Health Network, Toronto (T.K. Marras, S.K. Brode, J.C. Kwong); Institute for Clinical Evaluative Sciences, Toronto (M.A. Campitelli, H. Lu, H. Chung, A.S. Gershon, J.C. Kwong); West Park Healthcare Centre, Toronto (S.K. Brode); Public Health Ontario, Toronto (A. Marchand-Austin, J.C. Kwong, F.B. Jamieson); Oregon Health and Science University, Portland, Oregon, USA (K.L. Winthrop); Sunnybrook Health Sciences Centre, Toronto (A.S. Gershon)

Main Article

Table 3

Survival estimates for patients with pulmonary NTM and for matched controls, Ontario, Canada, 2001–2013*

Group
 Any NTM (isolation or disease)
NTM isolation only
NTM disease
Total
 5-y survival, %
 HR (95% CI)
 Total
 5-y survival, %
 HR (95% CI)
 Total
 5-y survival, %
 HR (95% CI)
NTM 18,436 71.3 1.47 
(1.42–1.51) 9,967 76.1 1.33 
(1.27–1.39) 8,469 65.6 1.63 
(1.56–1.70)
Control
 18,436
 80.8
 1.00 (ref)
9,967
 82.6
 1.00 (ref)
8,469
 78.7
 1.00 (ref)
MAC 10,785 71.2 1.45 
(1.39–1.51) 5,242 75.9 1.33 
(1.25–1.41) 5,543 66.7 1.57 
(1.48–1.66)
Control
 10,785
 80.4
 1.00 (ref)
5,242
 82.3
 1.00 (ref)
5,543
 78.5
 1.00 (ref)
M. xenopi 4,668 68.3 1.54 
(1.45–1.64) 2,693 74.5 1.32 
(1.22–1.44) 1,975 59.9% 1.84 
(1.69–2.01)
Control
 4,668
 79.9
 1.00 (ref)
2,693
 81.5
 1.00 (ref)
1,975
 77.7%
 1.00 (ref)
M. fortuitum 890 76.4% 1.39 
(1.21–1.60) 654 78.8 1.47 
(1.24–1.73) 236 69.7 1.25 
(0.96–1.63)
Control
 890
 84.9%
 1.00 (ref)
654
 86.4
 1.00 (ref)
236
 80.7
 1.00 (ref)
M. abscessus 363 80.5 1.45 
(1.09–1.92) 162 82.2 1.39 
(0.94–2.07) 201 79.2 1.49 
(1.00–2.21)
Control
 363
 86.6
 1.00 (ref)
162
 85.7
 1.00 (ref)
201
 87.3
 1.00 (ref)
M. kansasii 236 60.2 2.29 
(1.76–2.97) 92 55.3% 2.02 
(1.37–3.00) 144 63.5 2.53 
(1.78–3.58)
Control
 236
 84.0
 1.00 (ref)
92
 85.3%
 1.00 (ref)
144
 83.0
 1.00 (ref)
Other species 1,494 77.7 1.28 
(1.13–1.43) 1124 80.0% 1.20 
(1.04–1.38) 370 70.7 1.51 
(1.22–1.88)
Control 1,494 82.4 1.00 (ref) 1124 83.2% 1.00 (ref) 370 79.8 1.00 (ref)

*Matched by age (years), sex, index date (± 90 d), and propensity score (estimating the patient-level likelihood of species–condition combinations) value within 0.2 × SD of the exposed patient. NTM isolation was defined as 1 positive sputum specimen for NTM. NTM disease was defined as >1 positive sputum for the same species or 1 positive bronchoscopic or biopsy specimen. Controls were persons without NTM matched by age, sex, index date, and propensity score. HR, hazard ratio; MAC, Mycobacterium avium complex; NTM, nontuberculous mycobacterium; ref, referent.

Main Article

1These authors contributed equally to this article.

Page created: February 17, 2017
Page updated: February 17, 2017
Page reviewed: February 17, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external